Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia

Nemonoxacin, a novel nonfluorinated quinolone, exhibits potent in vitro and in vivo activities against community-acquired pneumonia (CAP) pathogens, including multidrug-resistant Streptococcus pneumoniae. Patients with mild to moderate CAP (n = 265) were randomized to receive oral nemonoxacin (750 m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: van Rensburg, Dirkie J. J., Perng, Reury-Perng, Mitha, Ismail H., Bester, Andrè J., Kasumba, Joseph, Wu, Ren-Guang, Ho, Ming-Lin, Chang, Li-Wen, Chung, David T., Chang, Yu-Ting, King, Chi-Hsin R., Hsu, Ming-Chu
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology (ASM) 2010
Materias:
Clinical Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2944601/
https://ncbi.nlm.nih.gov/pubmed/20660689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00295-10
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares